SANOFI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.86 EUR | -1.15% |
|
-5.70% | -0.98% |
| 05-15 | Transcript : Sanofi Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM | |
| 05-14 | Global markets live: Apple, Sony, Vodafone, Booking, Walmart... |  |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.98% | 121B | - | ||
| +32.09% | 693B | C+ | ||
| +29.39% | 584B | B | ||
| -1.34% | 372B | C+ | ||
| +20.34% | 332B | B- | ||
| +7.39% | 294B | C+ | ||
| +14.25% | 239B | B+ | ||
| -3.03% | 211B | A+ | ||
| +10.02% | 210B | B- | ||
| +8.49% | 168B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SAN Stock
- SNW Stock
- Ratings Sanofi
